<DOC>
	<DOCNO>NCT00003684</DOCNO>
	<brief_summary>RATIONALE : Theophylline may help relieve shortness breath patient cancer . It yet know whether theophylline effective treatment shortness breath . PURPOSE : Randomized phase III trial determine effectiveness theophylline treat shortness breath patient cancer .</brief_summary>
	<brief_title>Theophylline Treating Cancer Patients With Shortness Breath</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether theophylline improve dyspnea rating patient cancer short breath evidence respiratory muscle weakness . II . Determine whether drug improve ability perform daily activity group patient . III . Determine whether drug improve objective measure lung function ( e.g. , FEV-1 , FVC ) maximum inspiratory pressure patient . IV . Determine whether serum theophylline level relate magnitude effect observe patient population . V. Determine whether drug improve global rating quality life patient group . OUTLINE : This randomize , double blind , multicenter study . Patients stratify accord complete 6 minute walk test versus . Patients receive either oral theophylline placebo daily 3 day . In absence dose limit toxicity ( DLT ) , patient receive increase dose additional 4 day . In presence DLT , patient receive decrease dose treatment stop . Following completion 7 day study period , patient may give option continue active drug placebo 1 additional month unless toxic side effect develop . Quality life assess day 1 8 end additional 1 month period . PROJECTED ACCRUAL : A total 60 patient ( 30 arm ) accrue study .</detailed_description>
	<mesh_term>Theophylline</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven diagnosis cancer FEV1/FVC least 80 % predict OR FEV1/FVC le 80 % AND improvement FEV1 le 15 % use bronchodilator Maximum inspiratory pressure great 50 cm water Oximetry least 90 % Rating dyspnea `` moderate '' `` severe '' verbal rating scale ( VRS ) `` none , mild , moderate , severe '' describe `` usual breathlessness '' walk past 24 hour Score pain `` none '' `` mild '' VRS `` none , mild , moderate , severe '' `` unusual pain '' past 24 hour PATIENT CHARACTERISTICS : Age : 16 Performance status : Not specify Life expectancy : Greater 10 day Hematopoietic : Hemoglobin least 8.5 g/dL Hepatic : AST/ALT great 2 time upper limit normal ( ULN ) No liver disease Renal : Creatinine great 2 time ULN No kidney disease Cardiovascular : No acute congestive heart failure Greater 3 month since prior myocardial infarction No coronary artery disease cardiac stimulation might prove harmful ( i.e. , unstable angina ) No uncontrolled hypertension Pulmonary : See Disease Characteristics Other : Folstein MiniMental Status Exam score least 24 Able ( i.e. , sufficiently fluent ) willing complete quality life questionnaire assessment either English French No history clinically significant allergy intolerance theophylline , aminophylline , methylxanthines No active peptic ulcer disease No uncontrolled hyperthyroidism PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 14 day since prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 2 month since prior initiation hormonal therapy Hormones appetite stimulant allow receive 2 week No concurrent oral contraceptive Concurrent steroid allow take least 1 week prior study Concurrent inhale oral corticosteroid allow take least 1 week prior study No concurrent initiation new hormonal manipulation Radiotherapy : At least 28 day since prior radiotherapy include lung treatment field No concurrent radiotherapy include lung treatment field Surgery : Not specify Other : No concurrent digitalis glycoside , lithium , coumarin anticoagulant , xanthine , cimetidine , quinolone antibiotic ( e.g , ciprofloxacin norfloxacin ) , macrolide antibiotic ( e.g. , erythromycin ) , fluvoxamine , calcium channel blocker Concurrent nebulized inhaled cromolyn , nedocromil , beta2agonists , ipratropium , opioids , benzodiazepine , oxygen , diuretic allow dose stable 1 week prior study No concurrent paracentesis ( i.e. , thoracentesis ) No concurrent blood transfusion</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>pulmonary complication</keyword>
	<keyword>quality life</keyword>
</DOC>